KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) EBIAT (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of EBIAT data on record, last reported at $273.6 million in Q4 2025.

  • For Q4 2025, EBIAT rose 90.32% year-over-year to $273.6 million; the TTM value through Dec 2025 reached $404.6 million, up 78.65%, while the annual FY2025 figure was $391.0 million, 72.66% up from the prior year.
  • EBIAT reached $273.6 million in Q4 2025 per ACAD's latest filing, up from $71.8 million in the prior quarter.
  • Across five years, EBIAT topped out at $273.6 million in Q4 2025 and bottomed at -$113.1 million in Q1 2022.
  • Average EBIAT over 5 years is $9.3 million, with a median of -$6.7 million recorded in 2021.
  • Peak YoY movement for EBIAT: plummeted 139.77% in 2023, then skyrocketed 2897.22% in 2024.
  • A 5-year view of EBIAT shows it stood at -$43.1 million in 2021, then increased by 3.18% to -$41.7 million in 2022, then surged by 209.76% to $45.8 million in 2023, then skyrocketed by 213.87% to $143.7 million in 2024, then surged by 90.32% to $273.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were $273.6 million in Q4 2025, $71.8 million in Q3 2025, and $40.2 million in Q2 2025.